Cosmo Pharmaceuticals (CMOPF) Stock Price, News & Analysis

0.00 (0.00%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
382 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
CMOPF stock logo

About Cosmo Pharmaceuticals Stock (OTC:CMOPF)

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

CMOPF Stock Price History

CMOPF Stock News Headlines

Cosmo Announces Leadership Changes
Q4 2023 Paysign Inc Earnings Call
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Pupils unwell after school lab chemical spill
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV CMOPF
COSMO Pharmaceuticals SA (COPN)
See More Headlines
Receive CMOPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cosmo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Drug Manufacturers - General
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Not Optionable
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Mauro Severino Ajani (Age 69)
    Founder & Executive Chairman
    Comp: $425k
  • Mr. Alessandro E. Della Cha LL.M (Age 61)
    CEO & Executive Director
    Comp: $1.12M
  • Mr. Ngo Dinh Nhan (Age 45)
    President of Cosmo Intelligent Medical Devices
  • Mr. Giulio Evangelisti (Age 54)
    SVP of Manufacturing, Service and Security (IMD)
  • Mr. Niall Donnelly (Age 52)
    Chief Financial Officer
  • Mr. Marco Lecchi (Age 60)
    Chief Operating Officer
  • Mr. Davide Malavasi (Age 51)
    Qualified Person & Technical Director
  • Mr. Luigi Longo (Age 45)
    Chief Scientific Officer
  • Ms. Hazel Winchester (Age 53)
    Head of Investor Relations
  • Mr. Biagio Vigano (Age 50)
    Chief People Officer

CMOPF Stock Analysis - Frequently Asked Questions

How have CMOPF shares performed in 2024?

Cosmo Pharmaceuticals' stock was trading at C$52.65 at the beginning of 2024. Since then, CMOPF stock has increased by 44.3% and is now trading at C$76.00.
View the best growth stocks for 2024 here

How do I buy shares of Cosmo Pharmaceuticals?

Shares of CMOPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTC:CMOPF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners